Evidence map›Paper›PMID 31396208›Full record

ArticleFrontiers in immunology2019

Toll-Like Receptor 2 Release by Macrophages: An Anti-inflammatory Program Induced by Glucocorticoids and Lipopolysaccharide.

Jessica Hoppstädter, Anna Dembek, Rebecca Linnenberger, Charlotte Dahlem, Ahmad Barghash, Claudia Fecher-Trost, Gregor Fuhrmann, Marcus Koch, Annette Kraegeloh, Hanno Huwer and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Myeloid TLR2 signaling amplifies immunopathology in influenza-infected murine neonates.American journal of respiratory cell and molecular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Jessica HoppstädterDepartment of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany.
Anna DembekDepartment of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany.
Rebecca LinnenbergerDepartment of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany.
Charlotte DahlemDepartment of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany.
Ahmad BarghashDepartment of Computer Science, German Jordanian University, Amman, Jordan.
Claudia Fecher-TrostDepartment of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Homburg, Germany.
Gregor FuhrmannHelmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany.
Marcus KochINM-Leibniz Institute for New Materials, Saarbrücken, Germany.
Annette KraegelohINM-Leibniz Institute for New Materials, Saarbrücken, Germany.
Hanno HuwerDepartment of Cardiothoracic Surgery, Völklingen Heart Centre, Völklingen, Germany.
Alexandra K KiemerDepartment of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany.
Saarland University · DELeibniz-Institute for New Materials · DEGerman Jordanian University · JOHelmholtz Institute for Pharmaceutical Research Saarland · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoids (GCs) are widely prescribed therapeutics for the treatment of inflammatory diseases, and endogenous GCs play a key role in immune regulation. Toll-like receptors (TLRs) enable innate immune cells, such as macrophages, to recognize a wide variety of microbial ligands, thereby promoting inflammation. The interaction of GCs with macrophages in the immunosuppressive resolution phase upon prolonged TLR activation is widely unknown. Treatment of human alveolar macrophages (AMs) with the synthetic GC dexamethasone (Dex) did not alter the expression of TLRs -1, -4, and -6. In contrast, TLR2 was upregulated in a GC receptor-dependent manner, as shown by Western blot and qPCR. Furthermore, long-term lipopolysaccharide (LPS) exposure mimicking immunosuppression in the resolution phase of inflammation synergistically increased Dex-mediated TLR2 upregulation. Analyses of publicly available datasets suggested that TLR2 is induced during the resolution phase of inflammatory diseases, i.e., under conditions associated with high endogenous GC production. TLR2 induction did not enhance TLR2 signaling, as indicated by reduced cytokine production after treatment with TLR2 ligands in Dex- and/or LPS-primed AMs. Thus, we hypothesized that the upregulated membrane-bound TLR2 might serve as a precursor for soluble TLR2 (sTLR2), known to antagonize TLR2-dependent cell actions. Supernatants of LPS/Dex-primed macrophages contained sTLR2, as demonstrated by Western blot analysis. Activation of metalloproteinases resulted in enhanced sTLR2 shedding. Additionally, we detected full-length TLR2 and assumed that this might be due to the production of TLR2-containing extracellular vesicles (EVs). EVs from macrophage supernatants were isolated by sequential centrifugation. Both untreated and LPS/Dex-treated cells produced vesicles of various sizes and shapes, as shown by cryo-transmission electron microscopy. These vesicles were identified as the source of full-length TLR2 in macrophage supernatants by Western blot and mass spectrometry. Flow cytometric analysis indicated that TLR2-containing EVs were able to bind the TLR2 ligand Pam

Indexed as

DexamethasoneGlucocorticoidsHumansImmune ToleranceImmunosuppressive AgentsLipopolysaccharidesMacrophages, AlveolarToll-Like Receptor 2DexamethasoneGlucocorticoidsImmunosuppressive AgentsLipopolysaccharidesTLR2 protein, humanToll-Like Receptor 2corticosteroidexosomeinnate immunitymicrovesiclepulmonary macrophage

Identifiers

PMID31396208
PMCPMC6664002
OpenAlexW2963662794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.